Cambridge, MA, United States of America

James Rasmussen

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 2006-2013

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of James Rasmussen in Disease Treatment

Introduction

James Rasmussen is an accomplished inventor based in Cambridge, MA (US). He holds three patents that focus on novel methods for treating diseases using random copolymers. His work has significant implications for the treatment of autoimmune diseases, particularly multiple sclerosis.

Latest Patents

Rasmussen's latest patents include methods of treating disease with random copolymers. These inventions relate to the administration of random copolymers comprising amino acids such as tyrosine (Y), phenylalanine (F), alanine (A), and lysine (K). The patents detail treatment regimens that involve administering these formulations at intervals greater than 24 hours or through sustained release formulations. Additionally, the inventions encompass methods for conducting a pharmaceutical business, including manufacturing, licensing, or distributing kits related to these formulations.

Career Highlights

Throughout his career, James Rasmussen has worked with notable companies such as Peptimmune, Inc. and Ares Trading S.a. His contributions to the field of pharmaceutical innovation have been recognized and have paved the way for advancements in treatment methodologies.

Collaborations

Rasmussen has collaborated with esteemed colleagues, including Bei Yu and Jianxin Zhang. Their combined expertise has further enhanced the development of innovative solutions in disease treatment.

Conclusion

James Rasmussen's work exemplifies the intersection of innovation and healthcare, particularly in the realm of autoimmune disease treatment. His patents and collaborations reflect a commitment to advancing medical science through inventive approaches.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…